Newsroom

eSignus Engages with Innovation at Startup Days 2025 in Bern

May 15, 2025
min read

eSignus proudly participated in Startup Days (SUD) 2025, a business and networking event held in Bern, Switzerland. This annual gathering convenes startups, investors, SMEs, and corporate entities in Switzerland, fostering connections, knowledge exchange, and the exploration of collaborative ventures. Startup Days casts a spotlight on pivotal themes such as sustainable solutions, healthcare, strategic startup investment, and the collective knowledge of founders. Daniel Hernández, CEO of eSignus, led our company's visit.

The event stands as a vital national platform for Switzerland's startup ecosystem designed to facilitate meaningful interactions, drive innovation, encourage robust knowledge sharing, and cultivate strong professional relationships. Ultimately, Startup Days provides a vibrant space dedicated to learning, growth, and uncovering synergistic opportunities. At eSignus, we are deeply committed to engaging in such events. Our participation underscores our dedication to staying at the forefront of industry developments and actively seeking out innovations that deliver tangible value to our clients and partners.

Share this post

Newsroom. Our Latest News, Stories and Updates

Mobility-Centro, the largest official Mercedes-Benz dealership in Spain, pioneering in the sale of vehicles with cryptocurrencies.

In a groundbreaking move, Mobility-Centro has partnered with Bit2Me and eSignus to accept cryptocurrencies for vehicle purchases, providing a secure and innovative payment option for their customers.

Seed Security: Choosing Between Tradition and Innovation

By comprehending the process of seed phrase creation, individuals can better appreciate the complex security measures that safeguard cryptocurrency and other digital assets.

We establish a working group with OBINEX to explore the integration of HASHWallet into their ecosystem

We are pleased to announce that we have initiated an exciting working group with OBINEX.